Practical recognition tools of immunoglobulin G serum antibodies against the myelin oligodendrocyte glycoprotein‐positive optic neuritis and its clinical implications by Lotan, I. et al.
42  |    Clin Exp Neuroimmunol. 2021;12:42–53.wileyonlinelibrary.com/journal/cen3
 
Received: 27 November 2020  |  Revised: 10 December 2020  |  Accepted: 10 December 2020
DOI: 10.1111/cen3.12623  
R E V I E W  A R T I C L E
Practical recognition tools of immunoglobulin G serum 
antibodies against the myelin oligodendrocyte glycoprotein- 
positive optic neuritis and its clinical implications
Itay Lotan1,2  |   Frederike C. Oertel3,4,5 |   Claudia Chien3,4,5,6 |   Susanna Asseyer3,4,5 |   
Friedemann Paul3,4,5,7 |   Hadas Stiebel- Kalish2,8
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Clinical and Experimental Neuroimmunology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society for 
Neuroimmunology.
1Department of Neurology and Neuro- 
Immunology Service, Rabin Medical Center, 
Petah Tikva, Israel
2Sackler School of Medicine, Tel Aviv 
University, Tel Aviv, Israel
3Experimental and Clinical Research 
Center, Max- Delbrück Center for Molecular 
Medicine and Charité – Universitätsmedizin 
Berlin, corporate member of Freie 
Universität Berlin, Humboldt- Universität zu 
Berlin, Berlin, Germany
4Berlin Institute of Health, Berlin, Germany
5NeuroCure Clinical Research Center, 
Charité – Universitätsmedizin Berlin, 
corporate member of Freie Universität 
Berlin, Humboldt- Universität zu Berlin, 
Berlin, Germany
6Department of Psychiatry 
and Psychotherapy, Charité – 
Universitätsmedizin Berlin, corporate 
member of Freie Universität Berlin, 
Humboldt- Universität zu Berlin, Berlin, 
Germany
7Department of Neurology, Charité 
– Universitätsmedizin Berlin, corporate 
member of Freie Universität Berlin, 
Humboldt- Universität zu Berlin, Berlin, 
Germany
8Department of Ophthalmology and Neuro- 
Ophthalmology Unit, Rabin Medical Center, 
Petah Tikva, Israel
Correspondence
Friedemann Paul, Experimental and Clinical 
Research Center, Max Delbrueck Center 
for Molecular Medicine and Charité – 
Universitätsmedizin Berlin, Lindenberger 





Myelin oligodendrocyte glycoprotein (MOG)- associated disease is an autoimmune 
disease of the central nervous system, associated with the presence of immunoglob-
ulin G serum antibodies against MOG. Recent data have allowed characterization of 
the clinical spectrum of MOG- associated disease, which is now considered a new 
disease entity, distinct from multiple sclerosis and neuromyelitis optica spectrum dis-
orders. Optic neuritis is the most common clinical presentation of MOG- associated 
disease in adults, both at disease onset and during the disease course, and has several 
distinct clinical and paraclinical features. Immunoglobulin G serum antibodies against 
MOG- positive optic neuritis is often bilateral and associated with optic disc swelling 
and a longitudinally extensive abnormal magnetic resonance imaging signal involving 
the retrobulbar portion of the optic nerve. The visual acuity during the acute attack is 
severely decreased, and the response to corticosteroids is often rapid and prominent. 
However, early relapses after steroid cessation are common, and a subset of patients 
is left with a permanent visual disability. In this review, we discuss the clinical and 
paraclinical features of immunoglobulin G serum antibodies against MOG- positive 
optic neuritis in adults, and focus on the distinctive features that can enable its early 
diagnosis. Therapeutical considerations at the acute stage and for relapse prevention 
are further deliberated.
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1  | INTRODUC TION
Myelin oligodendrocyte glycoprotein antibody disease 
(MOGAD) is an autoimmune disease of the central nervous 
system (CNS) that targets the MOG antigen present on the ex-
tracellular surface of the myelin sheath and oligodendrocytes.1 
The exact physiological role of MOG has not been fully delin-
eated. The fact that MOG is expressed relatively late during 
neural development suggests it might have a physiological role 
as a surface marker of oligodendrocyte maturation, as well as 
in myelin integrity, adhesion and cell surface interactions.1,2 
MOG antibodies (Abs) were initially described in patients with 
multiple sclerosis (MS). Recently improved antibody detec-
tion methods using cell- based assays (CBAs) of MOG in its full 
native confirmation form have allowed the identification of a 
subgroup of immunoglobulin G serum antibodies against MOG 
(MOG- IgG)- positive patients with a distinct, non- MS demyelin-
ating CNS disorder.3- 7
MOGAD shares several clinical similarities with aquaporin- 4 
(AQP4)- IgG- positive neuromyelitis optica spectrum disorders 
(NMOSD), including predilection to involve the optic nerves, the spi-
nal cord and the brainstem.2,8 Indeed, up to 42% of patients with 
the clinical NMOSD phenotype who are seronegative for AQP4 Abs 
test positive for MOG- IgG.9,10 However, MOG- IgG- positive patients 
might have more limited forms of the NMO spectrum (i.e. isolated 
recurrent optic neuritis [ON] or transverse myelitis11- 14), as well as 
other atypical NMOSD manifestations (i.e. seizures and encepha-
lopathy, brainstem encephalitis, cranial neuropathies, and aseptic 
meningitis12,15- 21).
Being a relatively new disease entity, the epidemiology of 
MOGAD has not been fully characterized. In a nationwide ep-
idemiological study from the Netherlands, the mean incidence 
of MOGAD between 2014 and 2017 was 0.16/100 000 per-
sons/year, with higher incidence rates in children than in adults 
(0.31/100 000/year vs 0.13/100 000/year, respectively).22 In a 
recent epidemiological study from the UK, the prevalence and in-
cidence rates of MOGAD were nearly twice as common as AQP4- 
IgG- positive NMOSD.23
Several sociodemographic features also differ in MOGAD 
compared with AQP4- IgG positive NMOSD, including younger 
age of onset, a higher proportion of Caucasian ethnicity and less 
pronounced female predominance in MOGAD.1,23- 30 These im-
munobiological and clinical distinctions have led many experts 
to consider MOGAD as a distinct clinical entity, separate from 
NMOSD.27,31- 35
With the accumulation of data from several retrospective stud-
ies that describe the clinical spectrum of MOGAD, it is now evident 
that ON represents the most common clinical manifestation of the 
disease in adults.8,22,26,28,29,33,36 Although some authors report a 
monophasic disease course in up to 50%28 and better long- term out-
comes in MOGAD,24,36,37 others have reported a relapsing course in 
70– 93% of patients,8,38 which might be associated with permanent 
neurological disability.8,13,28,38,39 Therefore, the early distinction of 
MOGAD from other demyelinating diseases is an important goal in 
the management of this disorder and in avoiding potentially harmful 
pharmaceutical choices.8,40,41
This review focuses on the clinical and paraclinical character-
istics of MOG- IgG- positive ON in adults. We discuss the distin-
guishing clinical and radiological features of MOG- IgG, as well as 
fundamental therapeutic considerations. Our goal is to provide cli-
nicians with a useful tool that will enable them to formulate early 
diagnostic suspicion of MOG- IgG ON and a timely therapeutical 
approach.
2  | THE COURSE OF OPTIC NEURITIS 
( ISOL ATED, RECURRENT, CHRONIC 
AND A SSOCIATED WITH NMOSD - LIKE 
SYNDROMES)
ON is the most common clinical manifestation of adult 
MOGAD.8,26,28,29,36 Possible disease courses include a single episode 
of isolated ON, recurrent ON, chronic relapsing inflammatory optic 
neuropathy (CRION)- like ON and ON associated with other neuro-
logical symptoms, such as transverse myelitis, brainstem syndromes, 
and cerebral pathology with seizures and encephalopathy.2,3,8,14,28,42-
 46 A large retrospective study of immune- mediated optic neuropa-
thies carried out in the UK identified MOG- IgG antibodies in 9% of 
patients with isolated ON, 20% of patients with relapsing ON and 
27% of patients with CRION.47 Jitprapaikulsa et al carried out a ret-
rospective study of 246 patients with at least two episodes of ON, 
of whom 186 had isolated recurrent ON and 60 had a subsequent 
neurological involvement. A total of 27 of the 186 (15%) patients 
with isolated relapsing ON and four of 60 patients (6.6%) with subse-
quent neurological involvement (i.e. transverse myelitis or brainstem 
or other cerebral syndromes) were MOG- IgG- positive. Among 14 
patients in this study who presented with CRION, four (29%) were 
MOG- IgG- positive.48 In other series, the percentage of MOG- IgG 
ON ranges between 6.3% in adults with inflammatory demyelinating 
disease of the CNS,5 to 27.5– 66.7% in selected cohorts of patients 
with isolated ON and CRION.40,42,49 In a population- based prospec-
tive study of ON in Denmark, MOG- IgG was detected in two out of 
51 patients (4%).50
Several retrospective studies have described the vari-
ous clinical manifestations of MOGAD during the past few 
years.8,13,22,28,36,38,51,52 The respective distribution of MOG- IgG ON 
and its clinical characteristics are summarized in Table 1.
Recent data suggest that ON as the initial symptom of MOGAD 
might be more frequent in the Asian versus the white population. A 
retrospective study that compared the clinical features of MOG- IgG 
ON between Asian and white races found it was present in 99% of 
Asian patients and 82% of white patients.53 In a Chinese study, 75% 
of MOGAD patients presented with isolated ON at disease onset, 
and 83.3% experienced at least one episode of ON during the dis-
ease course.54 However, in another study from Japan, the site of the 
first attack was the optic nerve in 17 out of 42 patients (40.5%).41
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A recent meta- analysis of the prevalence of AQP4- IgG and 
MOG- IgG ON reports a prevalence of AQP4- IgG of 27% in the 
Asian population and 4% in non- Asian adult patients with isolated 
ON, whereas MOG- IgG seroprevalence was 20% in Asians and 8% 
in non- Asians.55
3  | FREQUENCY OF BIL ATER AL ON
Simultaneous involvement of both optic nerves is characteristic of 
MOG- IgG ON and occurs more frequently than in other inflam-
matory optic neuropathies, including MS, NMOSD and idiopathic 
ON.37,46 In the study by Jitprapaikulsa et al, simultaneous bilateral 
ON was reported in 14 of 27 (52%) of MOG- IgG ON, in compari-
son with three of 24 (13%) of AQP4- IgG positive ON, two of 25 
(8%) of MS and 23 of 110 (21%) of double- seronegative patients.48 
Jarius et al reported bilateral ON in 15 of 50 patients (30%) at 
disease onset, and in 51.2% during the disease course.8 De Mol 
et al reported bilateral ON in 58% of adult MOGAD patients who 
presented with ON at disease onset.22 Juryncyk et al reported bi-
lateral ON in 24% of MOGAD at disease onset.28 In the series by 
Sepúlveda et al, simultaneous bilateral ON was observed in 37% of 
the patients with isolated ON.51 Coco- Calvo et al reported bilateral 
ON in 50 of 120 (41.7%) of MOGAD who presented with ON at 
disease onset.36 Zhao et al reported bilateral involvement at the 
initial presentation in 45% of MOG- IgG and 37.8% of the AQP4- 
IgG groups.56 Ramanathan et al reported bilateral ON in nine of 
13 (69.2%) AQP4- IgG- negative patients. In one patient, bilateral 
ON was followed by transverse myelitis, whereas in the other eight 
patients, the ON was isolated.14 In another series by Ramanathan 
et al, bilateral ON was reported in 42% of patients at disease 
onset.38 Similar findings were reported in a French retrospective 
multicenter study of MOGAD patients who experienced at least 
one episode of ON, in which 19 of 47 patients (40.4%) presented 
with bilateral simultaneous ON.57 Chen et al reported bilateral si-
multaneous ON during at least one of the attacks of ON in 32 of 
86 patients (37%).13
4  | ANTERIOR ON: NEURITIS A SSOCIATED 
WITH OPTIC DISC SWELLING
The presence of optic disc swelling is another salient characteristic 
of MOG- IgG ON (Fig. 1). Liu et al reported optic disc swelling in 21 
of 31 (67.7%) of MOG- IgG ON versus 22 of 67 (32.8%) of AQP4- IgG 
ON.58 Zhao et al reported optic disc swelling in 80% of MOG- IgG 
ON and 20% of AQP4- IgG ON,59 and Zhou et al found optic disc 
swelling in all 10 MOGAD patients who had attacks of ON during 
the disease course.54 Ramanathan et al reported prominent optic 
disc swelling at the presentation of ON.14 Of 19 adult patients with 
ON who had available fundoscopic examination, optic disc swelling 
was observed in 18 (95%).38 Chen et al noted disc edema in 36 of 
42 patients (86%) with available fundoscopic examination. In 52% of 
the cases, the disc edema was rated as moderate or severe.13 Biotti 
et al reported optic nerve head swelling in 70.2% of the events. In 
four cases in this series, peripapillary hemorrhages accompanied the 
presence of optic disc swelling.57
5  | PAIN CHAR AC TERISTIC S AT 
PRESENTATION ARE T YPIC AL OF MOG - IgG 
ON
Periorbital pain in the affected eye aggravated by eye movements 
is a common symptom in many types of inflammatory demyelinat-
ing ON. The rate of associated pain in MOG- IgG ranges between 
80% and 90%,13,54,57 which is comparable to the frequency of pain 
in MS and AQP4- IgG- positive ON.60,61 However, MOGAD patients 
typically describe a more severe pain50 and a diffuse headache or 
facial pain, as well as other types of pain. In a recent study that 
compared pain characteristics in MOGAD and AQP4- IgG- positive 
NMOSD, 50% of patients with MOGAD suffered mainly from 
headache or neck pain, including tension- type headache (in as-
sociation with recurrent ON), occipital neuralgia, cervicogenic- 
like headache and migraine that was aggravated in the context 
of MOGAD. In contrast, AQP4- IgG- positive NMOSD patients 
F I G U R E  1   (A) Retinal nerve fiber layer thickness and (B) color photograph of optic disc swelling in acute immunoglobulin G serum 
antibodies against myelin oligodendrocyte glycoprotein (MOG- IgG) optic neuritis. (A) A spectral domain (SD- HD) Cirrus OCT 4000- 2713 
(Cirrus HD; Carl Zeiss Meditec, Jena, Germany) of the optic nerve reveals bilateral swelling of the retinal nerve fiber layer. (B) A color 
photograph of the optic disc revealing 360° disc edema. OD, oculus dexter (right eye); OS, oculus sinister (left eye); RNFL, retinal nerve fiber 
layer
(a) (b)
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suffered mainly from myelitis- related neuropathic pain (82.6%), 
whereas headache and neck pain were reported less frequently 
(21.7%).62 In another study that evaluated the frequency and 
characteristics of headaches in MOG- IgG ON, 64 of 129 (49.6%) 
of the patients had at least one episode of ON associated with 
headaches. MOG- IgG- related ON is often associated with a florid 
intraorbital and perioptic inflammation of the anterior portion of 
the optic nerve, likely to involve meninges and nociceptive fibers 
around the optic nerve.8,63 The severity of the inflammation and 
the extent of the edema might explain the frequent and often se-
vere headache that precedes the visual deficit in MOGAD, some-
times misdiagnosed as migraine.64 This clinical constellation might 
be a differentiating feature compared with other forms of ON and 
should therefore trigger MOG- IgG testing.
6  | A SSOCIATED AUTOIMMUNE 
DISORDERS ARE UNCOMMON IN MOGAD
Autoimmune comorbidities and seropositivity for other au-
toantibodies that are relatively common in AQP4- IgG- positive 
NMOSD are less frequent in MOGAD.30,65,66 Concomitant cir-
culating autoantibodies are usually not detected in the con-
text of MOGAD.8,40,47,59 Elevated serum autoantibodies have 
been occasionally reported, including anti- thyroid peroxidase 
and anti- thyroglobulin, anti- nuclear antibody, anti- LGI1, and 
anti- NMDA.38,54,58,67,68
7  | CEREBROSPINAL FLUID AND BLOOD 
TESTS IN MOGAD
MOG is a glycoprotein that is selectively expressed on oligoden-
drocytes and is one of the constituents of the myelin sheath. Its 
presence on the myelin sheath’s surface makes it a target for anti-
body production and autoimmune responses in the CNS.33 Previous 
antibody- detecting assays were targeted to linear or denatured 
forms of the glycoprotein and identified non- pathogenic antibodies 
that were erroneously associated with MS. The current CBAs use 
the full- length conformationally intact MOG construct and a sec-
ondary class 1 IgG- binding antibody. The current CBAs include live 
CBAs, in- house fixed CBAs and commercial fixed CBAs. All CBAs 
have been shown to have high sensitivity and specificity in patients 
with a non- MS demyelinating CNS phenotype.4,69
The simultaneous occurrence of MOG- IgG and AQP4- IgG in the 
same patients is extremely uncommon. In most studies, double sero-
positivity was not observed.36 Nakajima et al reported a patient with 
gastric cancer who tested positive for both antibodies,40 and Zhao 
et al reported two patients with double seropositivity at the initial 
stage, who became MOG- IgG negative after 3 months.56 In a large 
retrospective cohort study that examined serum samples of 15 598 
patients, just 10 (0.06%) had dual seropositivity. In all cases, the ti-
ters of AQP- IgG were higher than the MOG- IgG titers.70
Lumbar puncture might show a pleocytic cerebrospinal fluid 
(CSF; >5 cells/μL) and elevated protein count. CSF pleocytosis 
in MOG- IgG ON is reported in 5– 47% of the cases, and is usually 
mild in isolated ON cases.38,54,57,59 When MOG- IgG ON occurs in 
combination with other neurological manifestations, the CSF white 
blood cell count might reach higher levels of >50 cells/μL13,51 or even 
>100 cells/μL.8,28 Elevated protein count is reported in 37– 54.5% of 
patients.13,38,54 Intrathecal synthesis of oligoclonal bands and ele-
vated IgG index, typically observed in MS, are much less frequent in 
MOGAD (and AQP4- IgG- positive NMOSD), where their occurrence 
has been reported in 0– 28%.8,13,22,30,36,38,48,54,57,59 A recent study in-
vestigating the CSF profile in 100 adult MOGAD patients confirmed 
these observations.71 In addition, the measles– rubella– varicella zos-
ter antibody index (MRZ reaction) in the CSF, considered a specific 
laboratory marker of MS, was absent in all MOGAD patients with 
available data.71
A few case series have reported elevated CSF opening pressure 
during MOG- IgG ON.54,72 As MOG- IgG is often bilateral and associ-
ated with prominent disc swelling, it might be initially misdiagnosed 
as idiopathic increased intracranial hypertension.72
8  | R ADIOLOGIC AL CHAR AC TERISTIC S
Several orbital magnetic resonance imaging (MRI) features have 
been shown to characterize MOG- IgG ON and help differentiate it 
from other forms of ON. Abnormal signal of the affected optic nerve 
during the acute attack is observed in most patients, with variable 
proportions ranging between 58.3% and 93.3% reported in differ-
ent series.8,40,59,73 Typical findings include T2- hyperintense lesions 
with swelling of the optic nerve and contrast enhancement.8,13,33,57
Although longitudinally extensive involvement of the optic 
nerve is typical for AQP4- IgG- positive NMOSD, it has been re-
ported in comparable proportions in MOGAD.13 Ramanathan et al 
compared the radiological characteristics of MOG- IgG- , AQP4- IgG- 
and MS- related ON patients during the first clinical presentation. 
Longitudinal ON, defined as the involvement of at least two contigu-
ous optic nerve segments, was observed in 18 of 19 (95%) of MOG- 
IgG ON and 11 of 11 (100%) AQP4- IgG ON.63
Although both MOG- IgG and AQP4- IgG ON might present 
with longitudinally extensive ON, the segment of the optic nerve 
involved varies between these two conditions. Zhao et al reported 
the involvement of the retrobulbar portion of the optic nerve 
in the majority (80%) of MOG- IgG patients, whereas in AQP4- 
IgG ON, the canalicular part of the optic nerve was more com-
mon (57.8%).59 In the series by Ramanathan et al, a retrobulbar 
involvement was observed in 53% of MOG- IgG ON versus 27% 
of AQP4- IgG ON and 23% of MS- ON, whereas the involvement 
of the intracranial portion of the optic nerve was observed more 
frequently in AQP4- IgG- positive ON.63 The involvement of the 
anterior part of the visual pathway in MOG- IgG ON that is often 
associated with the clinical finding of optic disc swelling might 
have a radiological correlate. Such findings of radiological swelling 
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of the optic nerve head were observed in 10 of 19 (53%) MOG- 
IgG- positive patients.63 In the French series reported by Biotti 
et al, the retrobulbar segment of the optic nerve was involved in 
93.3% of the cases.57
Perineural enhancement of the soft tissue around the optic 
nerve is another characteristic of MOG- IgG ON. In the series by 
Kim et al, such findings were reported in 33% of the cases5; Jarius 
et al reported a similar finding in 39.3% of the patients8; in the se-
ries by Akaishi et al, an extension of the inflammation with contrast 
enhancement of the intraorbital tissue was observed in 47.1% of pa-
tients.74 Chen et al observed perineural enhancement during at least 
one ON attack in 50% of the cases,13 whereas in the series by Zhou 
et al and by Lee et al, perineural enhancement was observed in 75% 
and 91.6% of the cases, respectively.42,54 Other intracranial anatom-
ical parts of the visual pathway, that is, the optic chiasm and optic ra-
diation, are involved more typically in AQP4- IgG- positive NMOSD, 
but might be involved in MOGAD as well. While Ramanathan et al 
reported these findings to be were very uncommon in MOGAD pa-
tients (5% of MOGAD had chiasmatic lesions and 0% had bilateral 
involvement of the optic tracts, in comparison with 64% and 45% of 
AQP4- IgG positive NMOSD, respectively),63 Chen et al reported in-
volvement of the optic chiasm in 12% and optic tract involvement in 
2%,13 and Akaishi et al reported sparing of the optic chiasm in MOG- 
IgG ON,74 Their occurrence was higher in other series: Etemadifar 
et al reported chiasmatic lesions in 25%, and post- chiasmatic lesions 
of the visual pathway in 16.6% of MOG- IgG ON during the first 
event;73 Zhao et al reported chiasmatic lesions in 15% and optic ra-
diation lesions in 5% of MOG- IgG ON.59
Other than the visual pathway, brain abnormalities have been 
reported in patients with MOG- IgG ON as well. In the series by 
Zhou et al, brain lesions were present in eight of 12 (66.7%) MOGAD 
patients.54 Similar abnormalities were less frequent in other se-
ries, ranging between 12.4% and 37%.5,36,40,48,57,63 When present, 
the brain abnormalities in MOGAD are usually described as non- 
specific or non- typical for MS.75,76 In some cases, large lesions that 
involve the white matter and internal capsule, multiple cortical and 
subcortical lesions, and thalamic and pontine lesions might be ob-
served.5,36,63 Active lesions have been shown to often present as 
gadolinium- enhancing, poorly delineated with a “cloud- like” mor-
phology.77 Some authors described several imaging features that 
might help to distinguish between MOGAD- and AQP4- positive 
NMOSD. These include the presence of cortical lesions and juxta-
cortical brain lesions that are more frequently observed in MOGAD, 
whereas the involvement of the area postrema, which is typical for 
NMOSD, is rare in MOGAD.78,79 In contrast, others found an over-
lapping pattern of brain lesions in the two conditions.80
9  | ADVANCED MAGNETIC RESONANCE 
IMAGING CHAR AC TERISTIC S
Due to the difference in cellular targets between AQP4- IgG 
and MOG- IgG, it would be expected that conventional MRI 
characteristics would differ between the two disease entities. 
However, there has yet to be a clear distinction found.35,81
Evaluation of advanced MRI metrics in NMOSD and MOGAD 
could offer more discriminatory power, and elucidate microstructural 
differences in the CNS between patients with NMOSD and MOGAD. 
Recently, Schmidt et al showed that despite no differences in the 
whole brain and deep grey matter volumes of the brain between 
MOG- IgG- seropositive patients from healthy controls, a decreased 
parallel diffusivity in the whole brain diffusion tensor analysis was 
found.82 Meanwhile, no differences in diffusion- weighted MRI met-
rics were found between AQP4- IgG- seropositive NMOSD patients 
and healthy controls, indicating that white matter tracts are more 
affected in MOGAD than in AQP4- IgG- positive patients.
Another study found that optic chiasm height and area measured 
from standard 3- D T1- weighted brain MRIs were significantly de-
creased in AQP4- IgG- positive patients with and without previous 
ON compared with healthy controls.83
Aside from localized damage, Chien et al found that in AQP4- 
IgG- positive patients, deep grey matter volumes are decreased with 
an increased history of combined NMOSD- related attack counts and 
disease duration.84 There are still discrepancies in findings regard-
ing deep grey matter volume differences in AQP4- IgG- seropositive 
NMOSD patients and healthy controls, where some studies find no 
significant differences,85 whereas other studies have found some 
decreases in volumes.82,84 There is evidence that deep grey mat-
ter involvement does occur, especially in children with MOG- IgG- 
seropositive autoimmune encephalitis.86 These findings increase the 
likelihood that deep grey matter regions of the brain are affected in 
adult MOGAD as well and should be further studied.
The discussed recent methods of evaluating advanced MRI met-
rics are yet to be studied in large adult MOGAD cohorts, and it re-
mains to be seen if advanced MRI metrics can detect microstructural 
changes due to ON in these patients.
10  | OPTIC AL COHERENCE TOMOGR APHY 
CHAR AC TERISTIC S
Optical coherence tomography (OCT) is an interferometric tech-
nique using low- coherent light to produce cross- sectional images 
of the retina. It thereby allows us to qualitatively and quantitatively 
analyze the three anterior neurons of the afferent visual system, 
as well as their degeneration; for example, in MOG- IgG- associated 
ON. In particular, the peripapillary retinal nerve fiber layer thick-
ness (pRNFL)— consisting of unmyelinated axons of retinal ganglion 
cells— and the macular ganglion cell layer itself (mostly measured in 
combination with the adjacent inner plexiform layer as ganglion cell/
inner plexiform) have become reliable OCT markers for retinal neu-
rodegeneration dependent and independent of ON.87
During the acute stage of MOG- ON, typical disc swelling is accom-
panied by corresponding pRNFL swelling seen on OCT (Fig. 1). After 
the acute stage of ON, retinal neurodegeneration ensues (measured 
by pRNFL and ganglion cell/inner plexiform). MOG- IgG- seropositive 
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patients are suggested to suffer from less severe retinal neurode-
generation per ON attack than AQP4- IgG- positive patients.74,86,88 
However, as MOGAD typically manifests with frequent ON attacks, 
accumulated thinning might ensue. Some patients reach pRNFL val-
ues <30 µm, after which further neurodegeneration is hard to detect 
due to flooring effects.89,90 Furthermore, one publication suggests 
that MOG- IgG- associated ON— as MS- associated ON— commonly 
leads to a temporal preponderance of retinal neurodegeneration.91 
The outer retinal layers were only sparsely investigated, but seemed 
unaffected by MOG- IgG ON.92 OCT studies in acute ON or with 
longitudinal analyses are also sparse in MOGAD. One study in a 
combined cohort of eyes with and without a history of ON found a 
progressive pRNFL, but not ganglion cell/inner plexiform thinning in 
MOG- IgG- seropositive patients,93 suggesting a potential additional 
ON- unrelated retinal pathology in MOGAD.
OCT technology is under constant development; acquisition, 
as well as postprocessing, is undergoing fast advancements. Novel 
OCT technologies allow, for example, the incorporation of volumet-
ric angiography images called OCT angiography (OCTA). Only one 
study applying OCTA in MOG- IgG ON so far showed a decrease in 
retinal vessel density.94
11  | SE VERIT Y OF VISUAL LOSS AT NADIR
The decrease in visual acuity during the acute stage of MOG- IgG 
ON is usually severe. In most series where this information is avail-
able, the visual loss at nadir was reported between counting finger 
and hand movements.5,13,48,54,58,95 This finding is comparable to that 
observed in AQP4- IgG positive ON and is significantly worse than 
that observed in MS.
12  | MOG - IGG ON HA S A 
UNIQUELY R APID RESPONSE TO IV 
METHYLPREDNISOLONE
Acute therapy for all types of ON consists of intravenous methyl-
prednisolone administered at a daily dosage of 500– 1000 mg for 
3– 7 days, followed by oral prednisone.33 The response to corti-
costeroid therapy is, in most cases of MOG- IgG ON, very fast and 
prominent. Zhou et al reported improvement of visual acuity to 0.8– 
1.0 after high- dose intravenous methylprednisolone in seven of 10 
patients (70%)54; Nakajima et al reported a complete response to 
steroids in seven of eight patients (87.5%)40; Biotti et al observed 
rapid and dramatic response to steroids in most cases.57
13  | STEROID -  CESSATION REL APSES ARE 
T YPIC AL OF MOG - IGG ON
Although the response to steroids is usually rapid, MOG- IgG 
ON might show a CRION- like clinical course characterized by 
steroid- dependency; that is, a tendency to recur after steroid ces-
sation or during tapering of oral steroids. In the series by Sepúlveda 
et al, three of 21 patients (14%) with recurrent ON presented CRION 
features.51 Liu et al reported that 11 of 31 patients (35.5%) with 
MOG- IgG ON relapsed when the steroid dose was reduced.58 Zhou 
et al reported a relapse during the reduction process of oral steroids 
or shortly (<1 month) after steroid cessation in five of six patients 
(83.3%).54 Ramanathan et al documented 103 relapses following 146 
episodes treated with a short course of oral prednisolone taper. In 
41 episodes, the relapse occurred toward the end of the taper, and 
in 63 episodes, relapse occurred after a mean duration of 2 months 
from treatment cessation.38
14  | PRE VENTIVE IMMUNOTHER APY
The topic of preventive immunotherapy in MOGAD is still a matter 
of debate. This is primarily driven by several observations that re-
ported a relatively low relapse risk in MOGAD, therefore suggesting 
that chronic immunotherapy might not be required.24,37 However, 
other studies report similar relapse rates in MOGAD as in NMOSD,48 
as well as a significant risk of disability accumulation.5,8 Some studies 
have shown a correlation between persistent MOG- IgG seropositiv-
ity and the risk of relapse. Jurynczyk et al reported that 41 of 57 pa-
tients (72%) with repeated MOG Abs testing at least 6 months apart 
remained seropositive. A total of 24 of the 41 patients (59%) who 
remained seropositive had a clinical relapse, whereas all those who 
became seronegative over time (14 of 57; 25%) were relapse- free.28 
Hyun et al obtained longitudinal serum samples from 10 MOGAD 
patients treated with maintenance immunotherapy. Two of five pa-
tients (40%) in whom MOG- IgG Abs remained positive had clinical 
relapses, whereas none of those who became seronegative had fur-
ther relapses.96 López- Chiriboga et al evaluated the risk of relapse in 
patients with an initial diagnosis of ADEM. Among 20 adult patients, 
eight showed persistent MOG- IgG seropositivity, and four had tran-
sient MOG- IgG seropositivity. Seven of eight patients (87.5%) with 
persistent MOG- IgG seropositivity and one of four (25%) with tran-
sient MOG- IgG seropositivity had further relapses of ON (n = 7) or 
myelitis (n = 1).97 Coco- Calvo et al evaluated the relationship be-
tween MOG- IgG titers at the time of initial disease presentation and 
disease course. Higher titers were associated with a more severe 
initial presentation, but were not predictive of higher relapse risk.98
Currently, there is no consensus on whether to start immunosup-
pressive treatment after the first clinical presentation in MOGAD. In 
an international survey distributed to clinicians who treat MOGAD, 31 
of 51 (60%) experts reported they usually start maintenance immuno-
therapy after the first attack, and 48 of 52 (92%) would start a mainte-
nance therapy after two or more attacks.99 Jurynczyk et al recommend 
continuing low- dose oral corticosteroids for 6 months after the initial 
attack and tailor the future therapeutic decision based on repeated 
MOG- IgG testing. In the case the MOG- IgG becomes negative, the 
patient can be weaned off therapy, whereas in the case of persistent 
seropositivity, continuation with oral corticosteroids for an additional 
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6 months and retesting the MOG- IgG serostatus or treatment with a 
steroid- sparing immunosuppressive agent is recommended.33 Other 
authors consider the recovery from the initial attack and suggest to 
start a maintenance immunosuppressive therapy in the case of signifi-
cant disability from the onset attack.26,100 Hegen and Reindl proposed 
a combined approach based on an individual risk– benefit evaluation 
that takes into consideration the severity and recovery from the acute 
attack, and the persistency of serum MOG- IgG.34
The current therapeutic approach for relapse prevention in 
MOGAD is largely adopted from NMOSD and focuses on steroid- 
sparing agents, such as azathioprine, mycophenolate mofetil and 
rituximab.99,101- 103 However, in contrast to AQP4- IgG- positive 
NMOSD, where rituximab is considered highly efficacious, there are 
several reports of lower efficacy in MOGAD.8,104,105 Recent reports 
suggest intravenous immunoglobulins, which has been proved effec-
tive in reducing relapse rate and improving neurological disability in 
pediatric MOGAD,106 might be an effective therapeutical option in 
adult MOGAD as well.107,108 Tocilizumab, an anti- interleukin- 6 agent 
that has been shown to reduce the relapse rate in NMOSD, has also 
shown similar efficacy in a few adult MOGAD patients.109,110
The common disease- modifying therapies used for relapse pre-
vention in MS are ineffective in NMOSD and are therefore not rec-
ommended in MOGAD.33,100 This concept is supported by several 
reports of the ineffectiveness of classic disease- modifying therapies 
(i.e. interferon- beta, fingolimod and natalizumab) in MOGAD.8,40,41,105
15  | RISK OF PERMANENT VISUAL 
DISABILIT Y FROM ON IN MOGAD
Although some studies report a more favorable outcome of MOG- 
IgG ON compared with AQP4- IgG positive ON, others have shown 
that a subset of patients might have a permanent visual disabil-
ity.24,36,37,111 Jarius et al documented visual impairment in 21 of 38 
(55.3%) of MOG- IgG patients with a history of ON and available 
outcome data. A total of 14 of the 38 patients (36.8%) were either 
functionally blind at last follow up in at least one eye or had a severe 
visual impairment (visual acuity [decimal] >0.1 and ≤0.5)8; Sepúlveda 
et al reported severe visual disability in seven of 27 patients (26%) 
with isolated ON. Recurrent clinical course and bilateral ON were 
associated with worse visual outcomes51; Matsuda et al documented 
a permanent visual field deficit in 14 of 18 patients (77.8%) with 
MOG- IgG ON112; Jurynczyk et al reported permanent visual disabil-
ity (defined as visual acuity of 6/36 or worse in at least one eye at 
last follow up) in 12 of 75 patients (16%). Interestingly, all patients 
with permanent visual loss had ON during the onset attack, and in 
nine of them, the visual disability resulted from the onset attack.28 In 
the series by Kim et al, severe visual disability resulted from the first 
attack in three of four patients with severe sequelae.5
Some data suggest that early initiation of corticosteroid treat-
ment in MOG- IgG ON is associated with a better long- term visual 
outcome,113 as well as better preservation of the retinal nerve fiber 
layer observed in OCT.114
16  | DISCUSSION
The growing data accumulated during the past years support the no-
tion that MOGAD is a clinical entity distinct from MS and NMOSD. 
ON is the most common clinical manifestation of MOGAD. In this 
review, we delineate the distinctive clinical and radiological charac-
teristics of MOG- IgG ON. The information provided should enable 
clinicians who face a patient with ON to raise an early diagnostic 
suspicious of MOG- IgG.
The early recognition of MOG- IgG ON might have important 
therapeutic and prognostic implications. Although some studies 
suggest that MOG- IgG ON might have a better clinical recovery and 
more favorable visual outcomes than AQP4- IgG positive ON, sus-
tained visual impairment has been reported in MOGAD.8,14,51 These 
differences in visual outcomes after the acute event might evolve 
from lack of data on the timing of intravenous methylprednisolone 
from attack onset. The fact that early initiation of corticosteroid 
treatment has been shown to correlate with a better long- term visual 
outcome suggests that the permanent visual disability in MOG- IgG 
ON might result from delayed recognition and lack of tailored man-
agement aimed at offering hyperacute treatment and preventing the 
typical relapse of visual loss after steroid cessation. Similar observa-
tions have been previously reported in another cohort of patients 
with relapsing isolated ON and CRION, in which a hyperacute corti-
costeroid treatment was associated with better visual outcomes.115 
Although the MOG- IgG status of the patients in this cohort is not 
available, it seems plausible to assume that at least some of them 
were MOG- IgG positive. In animal models, it has been shown that 
the inflammatory process precedes the axonal degeneration by 
2 days,116 and that the irreversible axonal damage starts as early as 
5– 7 days from the inflammatory attack.117 Taken together, these no-
tions highlight the importance of early recognition and prompt ini-
tiation of treatment in MOG- IgG ON to prevent permanent axonal 
loss and visual disability. The short course of oral steroids prescribed 
to MS- related ON patients should not be given to MOGAD- ON pa-
tients, in whom undertreated relapses might jeopardize the visual 
outcome. However, the current data supporting this claim are based 
on retrospective studies and small cohorts. Larger, prospective trials 
are required to clarify the relationship between the timing of treat-
ment and visual outcome. A large prospective study that will address 
the possible impact of early corticosteroid therapy on the long- term 
visual disability in ON is currently being designed.
These unique characteristics of treatment response underscore 
the importance of early recognition of MOG- IgG ON.
17  | CONCLUSIONS
ON is the most common clinical manifestation of MOGAD. MOG- IgG 
often presents with simultaneous involvement of both optic nerves, 
is painful and is associated with prominent disc swelling. Orbital 
MRI shows an extensive abnormal signal of the anterior portion of 
the optic nerve and is associated with contrast enhancement of the 
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surrounding soft tissue. The visual deficit during the acute stage is 
severe, and although many patients show a good response to cor-
ticosteroids, many present with a typical relapse once short- course 
steroids are stopped, potentially compromising visual outcomes. 
Prospective trials are warranted to define the role of hyperacute ster-
oids and the optimal duration of treatment in acute MOG- IgG ON. 
Other urgent research needs to include identifying patients at high 
risk for relapses who would require maintenance immunotherapy and 
delineation of the most appropriate immunosuppressive regimen.
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